Group 1 - *ST Gaohong has been delisted on November 11, 2025, due to severe violations leading to mandatory delisting, marking the end of its journey in the A-share market [1][4] - The company engaged in systematic fraud for nearly nine years, inflating revenue and profits through false trading activities from 2015 to 2023, with a total inflated revenue of approximately 19.8 billion and inflated profit exceeding 76.2 million [1][4] - Following delisting, *ST Gaohong remains liable for compensation, and affected investors are encouraged to take legal action to protect their rights [1][4] Group 2 - The delisting process of *ST Gaohong reflects the zero-tolerance attitude of China's capital market regulatory system towards financial fraud, highlighted by a fine of 160 million and market bans for responsible individuals [2][4] - Investors who purchased shares between March 22, 2016, and April 29, 2024, and sold or still hold them after April 30, 2024, are eligible to file for compensation [2][4] - Affected investors should prepare relevant trading records and identification materials to submit compensation claims, with legal teams assisting in loss calculation to enhance the success rate of claims [2][4]

11名原告合计诉讼请求金额182.82万元。 东旭光电退市一年多之后，其财务造假案再起波澜，中信证券子公司因此被诉诸公堂。 证监会官网2025年3月底披露，河北、深圳证监局对东旭光电及东旭集团、东旭蓝天相关主体证券违法 行为作出行政处罚事先告知。 监管调查认定，2015年至2019年，东旭集团通过虚构业务等方式进行财务造假，累计虚增收入约478亿 元，同期虚增利润总额超130亿元，并存在债券欺诈发行行为。同期，东旭光电累计虚增营收约167亿 元、虚增利润超56亿元。同时，该公司2017年定增构成欺诈发行。 最终，东旭集团时任公司董事长、实际控制人李兆廷等43名责任主体，合计被罚17亿元，其中19名主要 责任人被采取五年以上直至终身证券市场禁入措施。 聚焦此次诉讼，披露显示，案件原告方为吴彩泉等11名投资者，被告为东旭光电、东旭集团、中信证券 华南公司等37名相关法人主体或自然人，案由为证券虚假陈述责任纠纷。 诉讼请求方面，11名原告合计主张经济损失182.82万元，要求东旭光电承担赔偿责任，其余36名被告承 担连带赔偿责任。 中信证券12月4日晚间披露，东旭光电证券虚假陈述责任纠纷案获河北石家庄中院受理，子公 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 一、公司披露诉讼进展 ST证通（维权）公告，截至2025年11月28日，公司收到深圳市中级人民法院向公司送达受理立案的投 资者索赔案件共计754件，涉案金额约6925.34万元。 公司表示，因该案件一审尚未判决，关于判决结果存在较大的不确定性，因此暂未计提预计负债，后续 将根据案件进展情况和会计准则的要求进行相应的会计处理。 （2）于2018年4月24日-2024年5月30日期间买入，并在2024年5月31日之后卖出或仍持有而亏损。 二、财务造假被严惩 据处罚决定书，需回溯到多年前收购的一家公司，2015年证通电子收购一公司70%股权，成为子公司， 将其纳入合并报表范围。2017年10月17日至12月4日，公司子公司与另一家公司签订6份采购合同，约定 向其采购存储设备等产品，合同金额合计2，177.4万元。2017年11月1日、2018年8月23日，子公司分别 与北京一点签订销售合同，约定将相应货物销售给北京一点，合同金额合计 2，648.14万元。上述采 购、销售业务涉及的货物未真实交付，最终导致公司2017年和2019年年报存在虚假记载。 责任编辑：韦子蓉 ...

Group 1 - The latest development in the Dongxu Optoelectronics case involves CITIC Securities' subsidiary, CITIC Securities South China Co., which is one of 37 defendants in a lawsuit concerning false statements, with a claimed amount of 1.8282 million yuan [1][2] - The lawsuit is based on allegations that Dongxu Optoelectronics' annual reports from 2015 to 2022 contained false records and significant omissions, and that the company engaged in fraudulent issuance of stocks in 2017 [1][2][3] - The court has determined that the case will proceed under a representative litigation procedure, with the plaintiffs being 11 investors seeking compensation for economic losses due to the alleged false statements [2][3] Group 2 - The lawsuit's plaintiffs are requesting a total compensation of 1,828,167.34 yuan for their losses, and they seek joint liability from other defendants besides Dongxu Optoelectronics [2] - The case involves historical issues related to the acquisition of Guangzhou Securities by CITIC Securities, with the potential losses already accounted for prior to the acquisition's completion [1][3] - Regulatory actions have been taken against Dongxu Group and Dongxu Optoelectronics for various violations, including fraudulent fundraising and financial misreporting, leading to significant penalties [4][5][6] Group 3 - Dongxu Group and Dongxu Optoelectronics have been found to have inflated revenues and profits significantly, with cumulative inflated revenues of 167.6 billion yuan and inflated profits of 56.27 billion yuan reported [6] - The regulatory bodies have imposed fines exceeding 16.6 billion yuan on Dongxu Group, Dongxu Optoelectronics, and related individuals, with some facing lifetime bans from the securities market [7][8] - The actions taken against these companies serve as a warning to other listed companies regarding the consequences of illegal activities, emphasizing the commitment of regulatory authorities to protect investors' rights [8]

Core Viewpoint - The company *ST Suwu (600200.SH) is set to be delisted from the Shanghai Stock Exchange after 25 years due to severe financial misconduct, including inflated revenues and misuse of funds, leading to a significant decline in its market value and investor uncertainty regarding compensation [1][12][14]. Group 1: Company Background and Transition - *ST Suwu, originally established in 1994 as a school-run enterprise, was once recognized as the "first stock in public education" and listed on the Shanghai Stock Exchange in 1999 [4]. - The company transitioned to a medical aesthetics focus under the control of the Qian siblings, who took over in 2018 [4][6]. Group 2: Financial Misconduct - Under the direction of Qian Qunshan, the company engaged in practices that inflated its revenue by 17.71 billion yuan and profits by 759.975 million yuan from 2020 to 2023, leading to a false portrayal of financial health [9][10][13]. - By the end of 2023, the company had 16.93 billion yuan in non-operating funds occupied by related parties, representing 96.09% of its net assets [10][13]. Group 3: Regulatory Actions and Consequences - The China Securities Regulatory Commission (CSRC) initiated investigations into *ST Suwu and its chairman Qian Qunshan, resulting in penalties for failing to disclose the actual controller and for financial misrepresentation [13][14]. - Qian Qunshan received a warning, a fine of 15 million yuan, and a 10-year ban from the securities market, while the company was fined 10 million yuan [14]. Group 4: Investor Impact and Future Steps - Following the delisting, approximately 67,400 shareholders face uncertainty regarding their rights and potential compensation for losses incurred due to the company's financial misconduct [1][15]. - Legal experts indicate that investors may pursue claims against the company and responsible parties if significant violations are confirmed [15].

Core Viewpoint - Luckin Coffee is facing allegations of employee exploitation, particularly regarding unpaid overtime and high work intensity, which has sparked significant public concern [2][5][8]. Employee Exploitation Allegations - Employees claim they work 12 hours daily but are only compensated for 9 hours, resulting in 3 hours of unpaid labor [5][8]. - The scheduling system reportedly misrepresents rest periods, as employees must remain on standby without pay during these times [5][8]. - High work intensity is highlighted, with strict performance metrics leading to a lack of breaks, even during designated rest times [8][9]. Financial Performance - In Q3 2025, Luckin Coffee reported total net revenue of 15.287 billion RMB, a 50.2% year-over-year increase, but net profit decreased by 1.9% to 1.28 billion RMB [14][15]. - The company experienced a significant rise in costs, with total costs and expenses reaching 13.5106 billion RMB, a 57.0% increase from the previous year [15][16]. - Delivery costs surged by 211.4% to 2.8892 billion RMB, now accounting for 19% of total revenue, indicating a substantial impact on profitability despite revenue growth [16]. Market Position and Future Outlook - Luckin Coffee is planning to return to the U.S. capital market after previously exiting due to financial fraud, with the CEO stating that this move could enhance the company's global presence [19][20]. - The company has shown recovery from past financial issues, achieving significant growth in revenue and profit, with a market share of 32% in China's ready-to-drink coffee sector [20][21]. - Analysts suggest that while the company has made substantial progress, regaining trust and navigating the complexities of re-listing on the U.S. market will be challenging due to its history of fraud [20][21].

Core Viewpoint - *ST Suwu has been forced to delist due to continuous financial fraud over the past four years, alongside a dispute over the agency rights of its key medical beauty product, AestheFill [2][6][12] Financial Misconduct - The company received a delisting decision from the Shanghai Stock Exchange due to "financial fraud" and other violations [2] - The China Securities Regulatory Commission (CSRC) issued an administrative penalty, confirming that the annual reports from 2020 to 2023 contained false records [4][7] - The fraudulent activities included concealing the actual change of control and inflating revenue, costs, and profits through non-commercial trade with related companies [6][7] Financial Impact - The inflated revenues for the years 2020 to 2023 were reported as follows: 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion, representing 26%, 26.39%, 21.26%, and 16.82% of the reported revenues respectively [7] - The inflated costs for the same years were 4.81 billion, 4.48 billion, 4.11 billion, and 3.55 billion, accounting for 37.08%, 35.47%, 28.40%, and 20.95% of the reported costs respectively [7] - The inflated total profits were 14.58 million, 20.27 million, 19.92 million, and 21.22 million, which were 2.9%, 51.65%, 26%, and 29.81% of the reported total profits respectively [7] Related Party Transactions - The company failed to disclose non-operating fund occupation by related parties, with balances at the end of each year from 2020 to 2023 being 127 million, 1.393 billion, 1.543 billion, and 1.693 billion, which represented 6.88%, 74.20%, 84.60%, and 96.09% of the reported net assets respectively [8] Agency Rights Dispute - The company is embroiled in a dispute over the agency rights of AestheFill, a key product that significantly contributed to its revenue [10][11] - AestheFill's sales accounted for 35.55% of the company's revenue in Q1 2025, with a gross profit contribution of 92.44 million, representing 45.77% of total gross profit [10] - The dispute escalated when Regen sent a termination letter to the company, demanding the cancellation of its exclusive distribution rights for AestheFill in mainland China [11] Market Response - The company’s medical beauty segment saw a revenue increase of 4225.65% in 2024, with a gross margin of 82.26% [13]

针对相应情况，监管拟对远大智能给予警告，并处以600万元罚款，同时拟对相关负责人给予警告及罚 款处罚。（中国经营报） 【#涉嫌虚增收入远大智能将被罚600万元#】因在确认收入方面涉嫌违法，远大智能或领600万元"罚 单"。日前，远大智能收到辽宁证监局出具的《行政处罚事先告知书》。经监管查明，远大智能涉嫌利 用伪造的《验收证明》提前确认电梯销售收入，涉嫌利用未实际履行的租赁协议确认租赁业务收入，导 致多份财报存在虚假记载。 ...

因财务造假，此前被立案处罚的江苏吴中医药发展股份有限公司(以下简称"*ST苏吴（600200）")被终 止上市。 12月1日晚，*ST苏吴发布公告称，公司收到上海证券交易所出具的《关于江苏吴中医药发展股份有限 公司股票终止上市的决定》，上交所决定终止公司股票上市。2025年12月9日，*ST苏吴股票进入退市 整理期，预计最后的交易日期为2025年12月29日。 实控人"隐身"6年。*ST苏吴未如实披露实际控制人，导致2018年至2023年年度报告存在虚假记载。 2018年2月，*ST苏吴控股股东苏州吴中投资控股有限公司发生股权变更，变更后，钱群山实际支配*ST 苏吴行为，成为*ST苏吴实际控制人。*ST苏吴2018年至2023年年度报告披露钱群英为实际控制人，存 在虚假记载。 公开资料显示，钱群英与钱群山为姐弟关系。钱群英出生于1968年10月，钱群山出生于1973年11月。钱 群英为中专学历。 财务造假4年。*ST苏吴虚增营业收入、营业成本和利润，导致2020年至2023年年度报告存在虚假记 载。具体来看，*ST苏吴多家子公司与多家关联公司开展无商业实质的贸易业务，虚增营业收入、营业 成本和利润。*ST苏吴 ...

因财务造假，此前被立案处罚的江苏吴中医药发展股份有限公司（以下简称"*ST苏吴"）被终止上 市。 12月1日晚，*ST苏吴发布公告称，公司收到上海证券交易所出具的《关于江苏吴中医药发展股份 有限公司股票终止上市的决定》，上交所决定终止公司股票上市。2025年12月9日，*ST苏吴股票进入 退市整理期，预计最后的交易日期为2025年12月29日。 令人不解的是，*ST苏吴停牌前股价表现反常，自11月19日起至11月25日，公司股票连续5个交易 日涨停。 *ST苏吴股票进入退市整理期的起始日为2025年12月9日，预计最后交易日期为2025年12月29日， 退市整理期的交易期限为15个交易日。公司股票在退市整理期届满后的5个交易日内由上海证券交易所 予以摘牌，公司股票终止上市。 医药行业分析师朱明军认为，这一系列严厉的处罚不仅是对*ST苏吴违法违规行为的直接回应，更 是监管层维护资本市场秩序坚定决心的体现。对于企业而言，退市意味着其将失去在公开市场的融资功 实控人"隐身"6年。*ST苏吴未如实披露实际控制人，导致2018年至2023年年度报告存在虚假记 载。2018年2月，*ST苏吴控股股东苏州吴中投资控股有限公 ...